title: High-dose atorvastatin ameliorates the uterine microenvironment in streptozotocin-induced diabetic rats.
abstract: Abstract The aim of this study was to investigate whether atorvastatin can ameliorate the uterine microenvironment in diabetes mellitus. Six non-diabetic (control) and 12 diabetic mature female Sprague-Dawley albino rats were used in this study. Diabetes was induced by intraperitoneal injections of 60 mg/kg streptozotocin, and 10 mg/kg/day of oral atorvastatin was administered for 4 weeks via orogastric tubes. The animals were euthanized, and blood samples were collected via cardiac puncture for biochemical analysis. Bilateral hysterectomy was performed for the histopathologic examination. Endometrial gland degeneration and stromal fibrosis scores concomitant with epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) immunoexpressions were analyzed. The endometrial gland degeneration scores, stromal fibrosis scores and VEGF immunoexpression was significantly lower, and the EGFR immunoexpression was significantly higher in the atorvastatin-treated diabetic rats when compared to the non-treated diabetic group, suggesting that atorvastatin ameliorates the uterine microenvironment in diabetes mellitus.
authors.affiliation: Department of Obstetrics and Gynecology .
authors.forename: Burak
authors.initials: B
authors.lastname: Zeybek
authors.forename: Mete
authors.initials: M
authors.lastname: Ergenoglu
authors.forename: Oytun
authors.initials: O
authors.lastname: Erbas
authors.forename: Nuri
authors.initials: N
authors.lastname: Yildirim
authors.forename: Ali
authors.initials: A
authors.lastname: Akdemir
authors.forename: Altug
authors.initials: A
authors.lastname: Yavasoglu
authors.forename: Huseyin
authors.initials: H
authors.lastname: Aktug
authors.forename: Dilek
authors.initials: D
authors.lastname: Taskiran
mesh_terms: D000818:Animals; D000069059:Atorvastatin; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D004717:Endometrium / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D005355:Fibrosis / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D006538:Heptanoic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014599:Uterus / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D042461:Vascular Endothelial Growth Factor A; D000069059:Atorvastatin; D066246:ErbB Receptors
keywords: Diabetes; endometrium; uterus